1-(1-Isobutylcyclobutyl)methanamine | 1015846-36-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(1-Isobutylcyclobutyl)methanamine
• 英文别名: [1-(2-methylpropyl)cyclobutyl]methanamine
• CAS: 1015846-36-2
• 化学式: C₉H₁₉N
• mdl: MFCD09971229
• 分子量: 141.25
• InChiKey: ZHRQQVCBZULLAE-UHFFFAOYSA-N

物化性质

• 沸点：
  161.5±8.0 °C(Predicted)
• 密度：
  0.855±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(1-Isobutylcyclobutyl)methanamine 、 2-(4'-fluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-7-(trifluoromethyl)benzo[d]oxazole-5-carbaldehyde 在 三乙酰氧基硼氢化钠 、 N,N-二异丙基乙胺 、 sodium tetrahydroborate 作用下， 以 氯仿 为溶剂， 以20 %的产率得到1-(2-(4'-fluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-7-(trifluoromethyl)benzo[d]oxazol-5-yl)-N-((1-isobutylcyclobutyl)methyl)methanamine
  参考文献：
  名称：

  [EN] CBL-B MODULATORS AND USES THEREOF
  [FR] MODULATEURS DE CBL-B ET LEURS UTILISATIONS

  摘要：

  本发明提供了用于抑制 Cb1-b 和治疗各种 Cb1-b 介导的疾病、失调或病症的化合物、其组合物和使用方法，这些疾病、失调或病症与调节涉及 Cb1-b 的免疫系统有关。化合物还可用于研究生物和病理现象中的 Cb1-b 酶；研究身体组织中发生的泛素化；以及比较评估体外或体内新的 Cb1-b 抑制剂或细胞周期、DNA 修复、分化以及先天性和适应性免疫的其他调节剂。

  公开号：

  WO2022272248A1

文献信息

• Compositions and methods for treating gastrointestinal hypomotility and associated disorders
  申请人：Ashburn T. Ted

  公开号：US20070010543A1

  公开（公告）日：2007-01-11

  This invention relates to methods for treating, preventing and/or managing GI hypomotility or a disorder associated with GI hypomotility in a subject including administering to the subject two compounds, where the first compound is a 5HT 3 agonist and where the combination of the two compounds results in an increase in GI motility. Also provided are compositions and kits for use in methods of the invention.
• [EN] SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS<br/>[FR] THIAZOLIDINEDIONE INDAZOLES, INDOLES ET BENZOTRIAZOLES SUBSTITUÉS UTILES EN TANT QUE MODULATEURS DES RÉCEPTEURS ? LIÉS AUX OESTROGÈNES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011149841A1

  公开（公告）日：2011-12-01

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
• [EN] CBL-B MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE CBL-B ET LEURS UTILISATIONS
  申请人：NIMBUS CLIO INC

  公开号：WO2022272248A1

  公开（公告）日：2022-12-29

  The invention provides compounds, compositions thereof, and methods of using the same for the inhibition of Cb1-b, and the treatment of a variety of Cb1-b-mediated diseases, disorders or conditions, associated with modulating the immune system implicating Cb1-b. Compounds are also useful for the study of Cb1-b enzymes in biological and pathological phenomena; the study of ubiquitination occurring in bodily tissues; and the comparative evaluation of new Cb1-b inhibitors or other regulators of cell cycle, DNA repair, differentiation, and innate and adaptive immunity in vitro or in vivo.

  本发明提供了用于抑制 Cb1-b 和治疗各种 Cb1-b 介导的疾病、失调或病症的化合物、其组合物和使用方法，这些疾病、失调或病症与调节涉及 Cb1-b 的免疫系统有关。化合物还可用于研究生物和病理现象中的 Cb1-b 酶；研究身体组织中发生的泛素化；以及比较评估体外或体内新的 Cb1-b 抑制剂或细胞周期、DNA 修复、分化以及先天性和适应性免疫的其他调节剂。